Novartis (NVS) is close to reaching a deal to acquire Cytokinetics (CYTK), Dana Cimilluca, Lauren Thomas and Laura Cooper of Wall Street Journal report, citing people familiar with the situation. The deal could be finalized as soon as this week, the paper notes. Cytokinetics has been running a sale process and it’s possible another suitor could reemerge, it adds. The Journal could not learn the potential price and other deal terms. Shares of Cytokinetics are up 10% to $102.70 following the report.
previous post